Lineage Cell Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Lineage Cell Therapeutics, Inc. had total assets of $113m, total liabilities of $69.2m and shareholders' equity of $44.5m. It held $40.8m in cash against $0 of debt.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Lineage Cell Therapeutics, Inc.: balance sheet, annual
Fiscal year	2009Dec 2009	2010Dec 2010	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Cash and equivalents	12	33	22	4	5	29	42	22	37	24	9	33	56	11	35	46	41	37
Receivables	—	—	0	0	1	1	1	0	0	0	0	—	51	0	1	1	1	1
Inventory	—	0	0	0	0	0	0	—	—	—	—	—	—	—	—	—	—	—
Total current assets	—	36	25	7	8	32	47	26	43	36	58	44	112	60	38	51	59	53
Goodwill	—	—	—	—	—	—	—	—	—	—	11	11	11	11	11	11	11	11
Total assets	—	53	46	30	58	75	95	143	173	102	125	108	175	124	101	113	113	106
Accounts payable	—	—	1	1	3	2	3	2	1	2	2	3	4	2	2	1	2	2
Deferred revenue (current)	—	0	0	0	0	0	0	1	0	0	0	0	52	9	11	7	3	2
Total current liabilities	—	2	3	4	7	7	12	9	7	7	6	8	47	19	18	14	11	8
Long-term debt	—	—	—	—	—	0	0	0	0	—	—	—	—	—	—	—	—	—
Total debt	0	0	0	0	0	0	0	2	0	—	0	0	0	0	0	0	0	0
Total liabilities	—	—	—	—	—	—	18	12	9	9	14	13	84	52	39	36	69	46
Shareholders' equity	11	38	29	10	15	36	26	118	163	92	113	96	92	73	63	78	45	61
Non-controlling interests and other (assets − liabilities − equity)	—	—	—	—	—	—	51	13	—	—	—	—	—	—	—	—	—	—
Shares outstanding	—	48m	49m	49m	57m	78m	90m	103m	127m	127m	150m	153m	169m	170m	175m	220m	243m	253m

US$ millions unless shown otherwise. Fiscal quarters.

Lineage Cell Therapeutics, Inc.: balance sheet, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Receivables	0	1	0	0	0	1	1	1
Total current assets	34	51	50	44	42	59	56	53
Goodwill	11	11	11	11	11	11	11	11
Total assets	97	113	112	91	90	113	110	106
Accounts payable	2	1	2	1	2	2	2	2
Deferred revenue (current)	8	7	7	5	4	3	2	2
Total current liabilities	14	14	13	11	9	11	8	8
Total liabilities	32	36	34	44	69	69	57	46
Shareholders' equity	66	78	79	48	22	45	54	61
Shares outstanding	189m	220m	228m	228m	230m	243m	249m	253m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: ALEC vs LCTX LCTX vs SRZN KROS vs LCTX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Lineage Cell Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Lineage Cell Therapeutics, Inc.